$SQFT Cashflow Statement | Understand Stock

$SQFT

$0.76 -$0.04 (4.99%) Close

$SQFT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization
Stock compensation
Bad debt expense
Gain on sale of real estate assets, net
Gain on extinguishment of government debt
Gain on deconsolidation of SPAC investment
Employee Bonuses paid with CDT stock
Net loss (gain) in fair value marketable securities
Conduit Pharmaceuticals Inc
All Other Than Conduit
Total net loss (gain) in fair value marketable securities

Net change in fair value SPAC Trust Account
Impairment of real estate assets
Accretion of original issue discount
Asset Impairment Charges
Amortization of financing costs
Amortization of above-market leases
Amortization of below-market leases
Amortization of deferred leasing costs
Straight-line rent adjustment

Changes in operating assets and liabilities:
Other assets
Deferred tax asset
Accounts payable and accrued liabilities
Accounts payable and accrued liabilities for the SPAC
Deferred leasing costs
Accrued real estate taxes
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Real estate acquisitions
Additions to buildings and tenant improvements
Investment in marketable securities
Proceeds from sale of marketable securities
Investment of SPAC IPO proceeds into Trust Account
Additions to deferred leasing costs
Withdrawals from Trust Account for SPAC taxes
Withdrawals from Trust Account for Redemption of SPAC Shares
Proceeds from sales of real estate, net
Net cash provided by investing activities

Cash flows from financing activities:
Proceeds from mortgage notes payable, net of issuance costs
Proceeds from government debt relief
Payment of debt issuance costs
Distributions to noncontrolling interests, net
Proceeds from initial public offering of SPAC
SPAC offering non-controlling interest adjustment
Issuance of Series A Common Stock, net of offering costs
Issuance of Common Stock Series A and warrants, net of offering costs
Repayment of mortgage notes payable
Repayment of note payable
Payment of extension costs, note payable
Payment of deferred offering costs
Distributions to noncontrolling interests
Contributions from noncontrolling interests
Redemption of SPAC shares
Repurchase of Series A Common Stock, at cost
Common Class A
Total repurchase of Series A Common Stock, at cost
Repurchase of Series D Preferred Stock, at cost
Dividends paid to Series D Preferred Stockholders
Dividends paid to Series A Common Stockholders
Net cash used in financing activities
Net (decrease) increase in cash equivalents and restricted cash
Cash, cash equivalents and restricted cash - beginning of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation

Supplemental disclosure of cash flow information:
Interest paid-mortgage notes payable
Mortgage Notes
Notes Payable
Total interest paid-mortgage notes payable

Income taxes paid
Potentially convertible common stock for SPAC (in shares)
Income taxes paid
Non-cash investing activities:
Paid building and tenant improvements from prior year
Private warrants from Conduit Pharmaceuticals
Non-cash financing activities:
Unpaid deferred offering costs
Issuance of stock for limited partnership interests
Payment of accrued bonus to ex-CFO with CDT stock
Distribution of CDT stock to employees
Unpaid building and tenant improvements
Dividends payable - Preferred Stock Series D
Series D Preferred Stock
Total dividends payable - Preferred Stock Series D

Comments